Princeton, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) announced recently that NanoRetinal, Inc., a biotechnology company developing nanoparticle-based therapies to restore and preserve vision in patients with inherited retinal diseases (IRDs) such as retinitis pigmentosa (RP), has received RDEP designation. FDA’s RDEP framework clarifies how sponsors of ultra rare, genetically defined diseases can meet the substantial evidence standard for regulatory approval with one pivotal study.
“We are thrilled with the RDEP designation and our chance to help prevent blindness by treating patients with the RLBP-1 retinal disease,” said Dr. John Cullity, NanoRetinal CEO. “Our patented technology restores retinal visual pigment helping preserve vision for RP patients.”
Based at Princeton Innovation Center BioLabs in Princeton, New Jersey, NanoRetinal is developing intravitreal protein therapeutics that restore the visual cycle, without the need for genetic modification. The lead program is RLBP1-associated retinal dystrophy.
Many RP variants are caused by genetic mutations which impair the structure and function of visual pigment, an essential element for vision. NAR-001 is engineered to increase the supply, photostability and durability of visual pigment; thus, offering hope for patients living with RP.
The FDA’s RDEP program came into effect in September 2025 to facilitate the review of treatments that, “… treat rare diseases with very small patient populations, significant unmet medical need and a known genetic defect.” NanoRetinal’s NAR-001 earned the FDA designation by targeting a specific genetic defect where no therapy currently exists, all with a view to preventing visual disability. “The RDEP pathway is tailor-made for the NAR-001 program,” Dr. Cullity said.
NanoRetinal, Inc. is a privately held biotechnology startup focused on developing nanoparticle treatments as licensed from the University of Bern in Switzerland to restore vision in patients with inherited retinal diseases.
For more information, please contact John Cullity, CEO, at info@nanoretinal.com or through the website: https://nanoretinal.com/
About FDA’s RDEP program: The FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) developed a new process under Rare Disease Evidence Principles (RDEP) to facilitate the approval of drugs to treat rare diseases.
FDA expects that substantial evidence of effectiveness may generally be established based on one adequate and well-controlled study that may be a single human trial, together with robust data that provides strong confirmatory evidence of the drug’s treatment effect.
Media Contact:
Christie Markowitz
Press contact for NanoRetinal
christie@markowitzstrategic.com
617-610-9563
Investor and Government Contact:
Mike Smith
IR and GR contact for NanoRetinal
mike@msbdinc.com
703-623-3834